Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Harvard Medical School (HMS and HSDM)
With
National Institute of Mental Health (NIMH)
Dartmouth-Hitchcock Medical Center
Commonwealth Research Center, Massachusetts
Eli Lilly and Company
This is a two-year open-label, randomized trial of the comparative effectiveness of clozapine versus olanzapine in patients with treatment refractory schizophrenia. The objective is to determine whether in a naturalistic setting olanzapine is a logical treatment choice (before using the more toxic clozapine) for some treatment refractory patients.
Age
20–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 20-60 years;
Diagnosis of treatment refractory schizophrenia or schizoaffective disorder;
BPRS score \> 21 (0-6) scale;
Either two 6-8 week trials of typical neuroleptics given at a dosage of 600 mg/day of CPZ or its equivalent or one 6-8 week trial of an atypical antipsychotic at a reasonable dose (i.e. risperidone 4-6 mg/day);
The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent;
Clinically appropriate for clozapine or olanzapine
